GRI Bio, Inc. (GRI) analyst actions
Rating and price-target actions on GRI in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the GRI overview →
3 measured GRI analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights | Press release | -6.80% | +5.60% | |
| GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results | Press release | -0.39% | -2.34% | |
| GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”) | Press release | +0.00% | -6.18% |
Keep exploring
More GRI: earnings → · SEC filings → · GRI overview →